Restoring Amd-Related Vision Loss With Sing Imt™. First-Year Results
Published 2024 - 42nd Congress of the ESCRS
Reference: PO421 | Type: Free paper | DOI: 10.82333/wk70-ay28
Authors: Eleni Papadopoulou* 1 , Iordanis Vagiakis 1 , Dimitrios Mikropoulos 1
1Ophthalmology,Ahepa University hospital ,Thessaloniki,Greece
Purpose
To present the results of the smaller-incision new-generation implantable miniature telescope (SING IMT) that was implanted in five patients in Ahepa University hospital one year ago.
Setting
Ahepa University Hospital, Thessaloniki, Greece
Methods
This retrospective single-center clinical study included phakic eyes with end-stage AMD treated at the Department of Ophthalmology. Presently, the SING IMT is indicated for monocular implantation to improve vision in eyes of patients at least 55 years of age with severe vision impairment and bilateral central scotomas associated with late-stage age-related macular degeneration. Candidates should retain adequate peripheral vision in the eye not receiving the implant. Patients with end-stage AMD who present an active choroidal neovascularisation within 6 months, have a history of other retinal or vascular disease, have uncontrolled glaucoma as well as corneal dystrophy are contraindicated for telescope surgery.
Results
In total, 5 patients participated in this study. The study population comprised 4 females and 1 male, who were all causasians. All patients had an improvement in near and distant visual acuity as well as quality of life. All five surgeries had no complications and intraocular pressure is still within normal limits to all patients.
Conclusions
This study evaluated the visual outcomes and safety of the SING IMT™ telescope prosthesis, the second generation of the IMT™ implant, in patients with bilateral moderate to profound central vision impairment due to advanced AMD.